-
Member
A couple of things of interest in an article about PEB in todays NBR.
David Darling mentioned that the initial share offer to institutional and habitual investors in the latest capital raising had been significantly oversubscribed and that the demand will flow on through to the tradeable rights which will come from the rights issue.
The company expects to have US licenses and to be market ready in March 2013. The first US customer has a private practice in New Jersey that has 120 urologists in it, about three times as many as there are in NZ.
I hope to make the trip south to attend the AGM on the 25th. Should be interesting.
-
........all sounds good Barney. Enjoy the AGM and please keep us posted. Exciting prospects for an ethical cutting edge co.
-
Member
The annual meeting held yesterday was a low key but interesting affair. Much of what was presented was information which has already been presented to shareholders over the last few months. However, there were some interesting points.
Healthscope and PEB will begin marketing cxbladder in Australia in about four weeks time.PEB expects Oryzon to start marketing in Spain and Portugal some time in October.
Singapore is likely to be the next country that PEB targets. Patents have been issued in Singapore, it is close to other Asian markets, is English speaking, and has tax agreements with NZ which means they are not taxed twice.
The recent share issue to institutions was 1.6 times over subscribed so augers well for the capital raising.
The general message from the company is that things are progressing well and it has been a satisfying year, especially on the science front.It will take a bit of time and marketing effort to get sales cranked up, with Colin Dawson making the point that medical specialists are naturally conservative in nature especially when introducing new products.David Darling commented that Parry Guilford was close to finalising a peer reviewed paper for release to the medical profession which should help in getting cxbladder into the marketplace.
-
Member
-
Originally Posted by barney
A couple of things of interest in an article about PEB in todays NBR.
David Darling mentioned that the initial share offer to institutional and habitual investors in the latest capital raising had been significantly oversubscribed and that the demand will flow on through to the tradeable rights which will come from the rights issue.
The company expects to have US licenses and to be market ready in March 2013. The first US customer has a private practice in New Jersey that has 120 urologists in it, about three times as many as there are in NZ.
I hope to make the trip south to attend the AGM on the 25th. Should be interesting.
Looks like DD was talking porkies
-
Member
-
Member
Based in Dunedin, New Zealand, Pacific Edge Diagnostics, Ltd., a leading developer of cancer diagnostic and prognostic technology, plans to open its first US franchise to market the company's bladder cancer detection test, Cxbladder(R), to urologists in the United States by the end of the year.
Hope they still hold enough cash to proceed its plan till the end of the year.
-
Member
-
Zs......Im pretty sure there's plenty of cash in the coffers for these and further developments?
-
Member
Originally Posted by GR8DAY
Zs......Im pretty sure there's plenty of cash in the coffers for these and further developments?
At least they will not burn them all today.
Tags for this Thread
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
|
|
Bookmarks